Navigation Links
Congress Sets New Course for Lung Cancer Research; Approves $20 Million for New Defense Department Program
Date:9/27/2008

WASHINGTON, Sept. 27 /PRNewswire-USNewswire/ -- Lung Cancer Alliance (LCA) announced today that Congress approved $20 million for a new lung cancer research program at the Department of Defense (DOD) -- a top LCA priority.

The president is expected to sign the bill containing the new lung cancer research program and the funding will be available in fiscal year 2009 which begins October 1.

"This is our top priority; this is the turning point. It is a breakthrough that lung cancer patients, their families and caregivers have been waiting for," said Laurie Fenton-Ambrose, LCA President & CEO. "By setting up this new program, Congress is finally acknowledging that the situation is urgent and that more research must be focused on lung cancer which is causing more deaths each year than breast, prostate and colon cancers combined."

Over 215,000 people will be diagnosed with lung cancer in the United States in 2008 and the majority will die in less than a year.

The new program, entitled the Peer Reviewed Lung Cancer Research Program, will be administered and funded by the DOD.

Former Transportation Secretary Norman Y. Mineta, a member of the LCA Board of Directors and a lung cancer survivor, said that DOD is "mission-oriented" and that the department's vast experience with cutting edge technology will accelerate improvements in the detection, diagnosis and treatment of lung cancer.

Congress started funding cancer research programs through DOD in the mid-nineties with a $25 million appropriation for breast cancer. Over the years a number of research programs have been added for other cancers, but not lung cancer -- until this breakthrough.

Fenton-Ambrose praised Congressman John P. Murtha (D-PA) and Senator Daniel K. Inouye (D-HI) for their leadership and commitment on the issue.

The legislation specifically notes that lung cancer is the most lethal of all cancers, taking more lives each year than all other major
'/>"/>

SOURCE Lung Cancer Alliance
Copyright©2008 PR Newswire.
All rights reserved

Page: 1 2

Related medicine news :

1. Updated MD-CARE Act Receives Final Congressional Approval
2. AVMA Addresses Livestock Health Issues Before U.S. Congress
3. Lilly to Sponsor Congressional Black Caucus Foundations Annual Legislative Conference
4. ADA Asks Congress to Strengthen Medicaid Oral Health Programs
5. Pro-Life Chair to Congress: We Cant Reduce Abortions By Promoting Abortion
6. Testifying Before Congress, Trust for Americas Health Urges FDA Spending Cap Until Realistic Budget Request is Made
7. Session highlights of the 1st World Congress on Interventional Therapies for Type 2 Diabetes
8. Statement From the Office of Congresswoman Stephanie Tubbs Jones
9. Bruker Daltonics Showcasing Novel Proteomics Solutions Based on Mass Spectrometry at the 7th HUPO World Congress 2008
10. 1st World Congress On Interventional Therapies for Type 2 Diabetes
11. Pelosi Statement on Congress Sending Consumer Product Safety Legislation to President
Post Your Comments:
*Name:
*Comment:
*Email:
(Date:12/4/2008)...c. 4 Aurora Health Care is ramping...upplements. Aurora,s Care Management,Clinical Lea...e all Aurora,caregivers about the benefits of Vit...idence that higher Vitamin D levels may improve ou...sis, certain muscle conditions and,seasonal depre...
(Date:12/4/2008)...as, Dec. 4 MiddleBrook,...ounced that it has opened its,administrative and ...rmantown,facility will continue to house certain ...research and development group. The newly leased ...to house up to 60 employees as MiddleBrook,grows....
(Date:12/4/2008)...ch., Dec. 4 BAPTIST HEALTH, a six-...he state,s largest health system, has,expanded it... Reuters -- a,solution that enabled the system,s ...entions and save more than $1 million. , "D... campus show that,CareFocus prompts approximately...
(Date:12/4/2008)...similar to those seen with standard dose of daunor... (HealthDay News) -- A high dose of the chemothera...ts with previously untreated acute myeloid leukemi...by the U.S. National Cancer Institute (NCI) show. ... This study included 633 patients, aged 16 to 60, ...
Breaking Medicine News(10 mins):Health News:Aurora Health Care Urges All Wisconsin Residents to Take Vitamin D 2Health News:Middlebrook Pharmaceuticals Opens Administrative and Sales Office in Westlake, Texas 2Health News:Middlebrook Pharmaceuticals Opens Administrative and Sales Office in Westlake, Texas 3Health News:Middlebrook Pharmaceuticals Opens Administrative and Sales Office in Westlake, Texas 4Health News:BAPTIST HEALTH Uses Real-Time Clinical Surveillance from Thomson Reuters to Lower Costs and Improve Quality in the Pharmacy 2Health News:BAPTIST HEALTH Uses Real-Time Clinical Surveillance from Thomson Reuters to Lower Costs and Improve Quality in the Pharmacy 3Health News:Higher Chemo Drug Dose Prolongs Lives of Leukemia Patients 2
...ans for the Northeast have been announced by the H...is expected to be opened by 2015//. The five exis...d in Dundalk, Drogheda, Navan, Monaghan. and Cavan... Walsh at Monaghan General Hospital last year cons...
...Municipal Corporation’s (BMC) Health Committee had...d conducted health camps// Chamunda Nagar and Shya...on have been reported. Their report has concluded ...te survey conducted by an NGO, Bal Hakk Abhiyan (B...
...e July 15 issue of Clinical Infectious Diseases sa...s could be very useful// in the event of an influe...atins lower "bad" cholesterol levels in the blood ... cholesterol. Statins may further protect the hear...
...he medicos who had resorted to the strike against ...h Minister Anbumani Ramadoss today said that not p...as not a punishment. 'It is not a punitive action....elease the salaries, we will do so,' he told repor...
Other Medicine News:Health News:Children In Slums Of Mumbai Might be Suffering From Malnutrition 2Health News:Statins Could Play Important Role In Influenza Pandemic 2
(Date:12/3/2008)...3 Wyeth Pharmaceuticals,...day that it has submitted a,marketing authorizati...ncy,(EMEA) for approval to market its investigati...V13) for infants and young children. Wyeth is see...ccal disease (PD) caused by the 13,serotypes incl...
(Date:12/2/2008)...ire-USNewswire/ -- Researchers using functional,M...e area of the brain,responsible for suppressing m...,stress-related psychiatric disorders. Results of ...eeting of the Radiological Society of North Americ...ssion and other stress-related disorders,traumat...
(Date:12/2/2008)...Newswire/ -- Horizon Therapeutics, Inc., a,privat...d that two pivotal,Phase 3 trials evaluating its ...met all primary endpoints. HZT-501, a novel, propr...ibuprofen and famotidine, demonstrated a,statisti...n-steroidal,anti-inflammatory drug (NSAID)-induce...
(Date:12/1/2008)...swire/ -- TargeGen has announced that an oral,pre...ter, US-based clinical,trial of TG101348 in myelo...at,the 2008 American Society of Hematology (ASH) ...e as follows:, Title: A Phase I... JAK2-Selective Inhibitor, in Pat...
Breaking Medicine Technology:Wyeth Submits European Marketing Authorization Application for its 13-Valent Vaccine for the Prevention of Pneumococcal Disease in Infants and Young Children 2Wyeth Submits European Marketing Authorization Application for its 13-Valent Vaccine for the Prevention of Pneumococcal Disease in Infants and Young Children 3Wyeth Submits European Marketing Authorization Application for its 13-Valent Vaccine for the Prevention of Pneumococcal Disease in Infants and Young Children 4Wyeth Submits European Marketing Authorization Application for its 13-Valent Vaccine for the Prevention of Pneumococcal Disease in Infants and Young Children 5Stress-Related Disorders Affect Brain's Processing of Memory 2Stress-Related Disorders Affect Brain's Processing of Memory 3Horizon Therapeutics Announces Two Pivotal HZT-501 Phase 3 Trials Meet Primary Endpoints 2Horizon Therapeutics Announces Two Pivotal HZT-501 Phase 3 Trials Meet Primary Endpoints 3Horizon Therapeutics Announces Two Pivotal HZT-501 Phase 3 Trials Meet Primary Endpoints 4Plexus Systems Inc and Aberdeen Group Co host March 27 Webinar on Manufacturing Efficiency 15096 1Plexus Systems Inc and Aberdeen Group Co host March 27 Webinar on Manufacturing Efficiency 15096 2Plexus Systems Inc and Aberdeen Group Co host March 27 Webinar on Manufacturing Efficiency 15096 3MRI Can Be Predictor of Post Treatment Prostate Cancer Spread 15095 1MRI Can Be Predictor of Post Treatment Prostate Cancer Spread 15095 2Mounting evidence shows red wine antioxidant kills cancer 2618 1Mounting evidence shows red wine antioxidant kills cancer 2618 2Mounting evidence shows red wine antioxidant kills cancer 2618 3New York City Staffing Company Charged With Violating H 1B Program Following U S Labor Department Finding Almost 243 Million in Back Wages Due 156 W 15090 1New York City Staffing Company Charged With Violating H 1B Program Following U S Labor Department Finding Almost 243 Million in Back Wages Due 156 W 15090 2
...ne Plus Minocycline Showed Substantial,Reduction o...ng-Remitting Multiple Sclerosis , Combination Trea...s and Was Well Tolerated , KANSAS CITY, Mo, May 4,...tudy showed that a combination of Copaxone,(glatir...otic,minocycline reduced T1 Gadolinium (Gd)-enhanc...
...th May 2007 - CeNeS Pharmaceuticals plc,(LSE: CEN)...otes,the publication of an independent study in th...hase II NMDA antagonist, CNS 5161. CeNeS,is develo...thic,pain. The independent study builds on the wor... , In the study reported in ,Synapse, Dr Anat Bie...
Other Medicine Technology:Treatment with Copaxone Plus Minocycline Showed Substantial,Reduction of Disease Activity in Patients with Active,Relapsing-Remitting Multiple Sclerosis 2Treatment with Copaxone Plus Minocycline Showed Substantial,Reduction of Disease Activity in Patients with Active,Relapsing-Remitting Multiple Sclerosis 3Treatment with Copaxone Plus Minocycline Showed Substantial,Reduction of Disease Activity in Patients with Active,Relapsing-Remitting Multiple Sclerosis 4Treatment with Copaxone Plus Minocycline Showed Substantial,Reduction of Disease Activity in Patients with Active,Relapsing-Remitting Multiple Sclerosis 5Treatment with Copaxone Plus Minocycline Showed Substantial,Reduction of Disease Activity in Patients with Active,Relapsing-Remitting Multiple Sclerosis 6Treatment with Copaxone Plus Minocycline Showed Substantial,Reduction of Disease Activity in Patients with Active,Relapsing-Remitting Multiple Sclerosis 7Treatment with Copaxone Plus Minocycline Showed Substantial,Reduction of Disease Activity in Patients with Active,Relapsing-Remitting Multiple Sclerosis 8Treatment with Copaxone Plus Minocycline Showed Substantial,Reduction of Disease Activity in Patients with Active,Relapsing-Remitting Multiple Sclerosis 9Treatment with Copaxone Plus Minocycline Showed Substantial,Reduction of Disease Activity in Patients with Active,Relapsing-Remitting Multiple Sclerosis 10Treatment with Copaxone Plus Minocycline Showed Substantial,Reduction of Disease Activity in Patients with Active,Relapsing-Remitting Multiple Sclerosis 11Treatment with Copaxone Plus Minocycline Showed Substantial,Reduction of Disease Activity in Patients with Active,Relapsing-Remitting Multiple Sclerosis 12Independent publication supports the profile of CeNeS phase II,compound, CNS 5161 2Independent publication supports the profile of CeNeS phase II,compound, CNS 5161 3
Large solid mallet with patented Ortho-Grip® silicone rubber handle.
Angled ring curette.
Perisoteal rasp for elevating, dissecting, and scraping.
Stainless steel bone clamp.
Medicine Products: